Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Slides:

Advertisements

Similar presentations

Miles D et al. Proc SABCS 2012;Abstract P

Advertisements

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.

William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Gianni L et al. Proc SABCS 2012;Abstract GS6-7.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial to Evaluate the Efficacy and Safety of Placebo + Trastuzumab + Docetaxel vs.

Assistant Professor of Medicine Dana-Farber Cancer Institute

ESMO 2011 Breast Cancer Trastuzumab in untreated MBC Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October.

Terapia Neoadiuvante Revisione delle evidenze scientifiche

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Baselga J et al. Proc SABCS 2010;Abstract S3-3.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, M.D., Ph.D., Javier Cortés, M.D., Sung-Bae Kim, M.D., Seock-Ah Im,

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.

A. Schema of NSABP B-27 trial comparing neoadjuvant AC to neoadjuvant AC followed by neoadjuvant docetaxel and to neoadjuvant AC followed by adjuvant docetaxel.

HER2 inhibition: when more is better?

A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.

Perez EA et al. SABCS 2009;Abstract 80.

HER2 and estrogen receptor status drive decisions regarding the use of neoadjuvant chemotherapy Neil Love, MD1, Kimberly L Blackwell, MD2, Eleftherios.

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting

Blackwell KL et al. SABCS 2009;Abstract 61

Vahdat L et al. Proc SABCS 2012;Abstract P

The Nurse View: Management of Pancreatic Cancer

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Swain SM et al. Proc SABCS 2012;Abstract P

New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.

Endocrine Combinations in HR-Positive MBC: The Future Is Now

The Nurse View.

Metastatic HER2+ Breast Cancer: Resistance

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer

The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.

Neoadjuvant Therapy for HER2-Positive Breast Cancer

Perspectives on Triple-Negative Breast Cancer

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Advanced NSCLC Without Actionable Mutations

Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

Her2-positive breast cancer: updating current best practice

سرطان الثدي Breast Cancer

Neoadjuvant Therapy in HER2-Positive Breast Cancer

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Managing CINV and Cachexia

Best Practices in Metastatic Colorectal Cancer

Managing gBRCA-Positive Metastatic Breast Cancer

Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

Untch M et al. Proc SABCS 2010;Abstract P

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Optimizing Neoadjuvant Treatment for Primary Breast Cancer

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

The Road to Quality Improvement in HER2-Positive Breast Cancer

Hormone Receptor-Positive Advanced Breast Cancer Introduction

Treatment of Locally Advanced Pancreatic Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Management of Advanced Pancreatic Adenocarcinoma

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.

Evaluating the Totality of Evidence

Uncovering the Right Sequence

Presentation transcript:

Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer

Program Goals

Changes to the Standard of Care for HER2-Positive Disease

CLEOPATRA Trial Results

CLEOPATRA Updated Overall Survival Analysis

Administering Dual HER2 Blockade

Are All Patients Candidates for Dual HER2 Blockade?

Pertuzumab /Trastuzumab /Docetaxel Safety Profile

Approaches in Different Scenarios

Neoadjuvant Therapy

Surgery in a Patient With Stage IV Breast Cancer

Investigational Trials

Abbreviations

References

References (cont)

References (cont)